Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,841 to 4,860 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Dapagliflozin 10mg vs Placebo: deaths from any cause | 41 of 625 54 of 625 | -2.1 points -5.1 to 0.9 | 1,250 | NCT04350593 Dapagliflozin in Respiratory Failure in Patients With COVID-19 |
| Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization or Death | 2 of 628 2 of 622 | -0.0 points -0.9 to 0.9 | 1,250 | NCT05894577 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) |
| Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 18 of 628 18 of 622 | -0.0 points -2.0 to 1.9 | 1,250 | NCT05894577 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) |
| Arm F - Montelukast vs Arm F - Placebo: serious adverse events | 6 of 628 3 of 622 | 0.5 points -0.6 to 1.6 | 1,250 | NCT05894577 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Leg/Foot Swelling as a Side Effect of Antihypertensive Medication at Six Months | 247 of 656 208 of 593 | 2.6 points -2.8 to 7.9 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting High Confidence in Measuring BP at Home at Six Months | 376 of 652 412 of 597 | -11.3 points -16.6 to -6.0 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Tiredness as a Side Effect of Antihypertensive Medication at Six Months | 437 of 656 376 of 593 | 3.2 points -2.1 to 8.5 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Cough as a Side Effect of Antihypertensive Medications at Six Months | 202 of 656 212 of 593 | -5.0 points -10.2 to 0.3 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Sexual Symptoms as a Side Effect of Antihypertensive Medication at Six Months | 174 of 656 132 of 593 | 4.3 points -0.5 to 9.0 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Frequent Urination as a Side Effect of Antihypertensive Medication at Six Months | 331 of 656 293 of 593 | 1.0 points -4.5 to 6.6 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Dizziness as a Side Effect of Antihypertensive Medication at Six Months | 247 of 656 232 of 593 | -1.5 points -6.9 to 3.9 | 1,249 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Routine Collection of Patient-Reported Health Status (KCCQ-12 Arm) vs Usual Care: deaths from any cause | 23 of 624 21 of 624 | 0.3 points -1.8 to 2.4 | 1,248 | NCT04164004 Patient-Reported Outcome Measurement in Heart Failure Clinic |
| Buprenorphine/Nx vs Methadone: serious adverse events | 38 of 727 45 of 520 | -3.4 points -6.5 to -0.6 | 1,247 | NCT00315341 Starting Treatment With Agonist Replacement Therapies (START) |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Rash, in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines. | 10 of 935 3 of 312 | 0.1 points -1.8 to 1.2 | 1,247 | NCT00453986 Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Serious Adverse Events (SAEs), in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines. | 7 of 935 1 of 312 | 0.4 points -1.1 to 1.3 | 1,247 | NCT00453986 Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Unsolicited Adverse Events (AEs), in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines. | 135 of 935 47 of 312 | -0.6 points -5.5 to 3.7 | 1,247 | NCT00453986 Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults |
| Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Adverse Events (AEs) Resulting in Emergency Room (ER) Visits, in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines. | 13 of 935 1 of 312 | 1.1 points -0.5 to 2.1 | 1,247 | NCT00453986 Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults |
| STRATIS vs Needle-Syringe: serious adverse events | 1 of 624 2 of 623 | -0.2 points -1.0 to 0.6 | 1,247 | NCT01688921 Jet Injection for Influenza |
| Daily Emollient vs Natural Skin: deaths from any cause | 1 of 614 1 of 633 | 0.0 points -0.7 to 0.8 | 1,247 | NCT03409367 A Community-based Assessment of Skin Care, Allergies, and Eczema |
| Daily Emollient vs Natural Skin: serious adverse events | 25 of 614 39 of 633 | -2.1 points -4.6 to 0.4 | 1,247 | NCT03409367 A Community-based Assessment of Skin Care, Allergies, and Eczema |
Code
curl "https://conductscience.org/api/comparisons/v1?page=243"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=243
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04350593-deaths",
"title": "Dapagliflozin 10mg vs Placebo: deaths from any cause",
"summary": "41 of 625 against 54 of 625; risk difference -2.1 points, 95% interval -5.1 to 0.9; NCT04350593, Dapagliflozin in Respiratory Failure in Patients With COVID-19",
"record": "/library/comparisons/NCT04350593-deaths",
"nct_id": "NCT04350593",
"kind": "deaths",
"participants": 1250,
"risk_difference": {
"value": -0.0208,
"lower": -0.05065850743845549,
"upper": 0.008788222285480565
},
"group_1": "41 of 625",
"group_2": "54 of 625",
"difference": "-2.1 points",
"interval": "-5.1 to 0.9",
"trial_title": "Dapagliflozin in Respiratory Failure in Patients With COVID-19"
},
{
"id": "NCT05894577-722f18ed",
"title": "Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization or Death",
"summary": "2 of 628 against 2 of 622; risk difference -0.0 points, 95% interval -0.9 to 0.9; NCT05894577, ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)",
"record": "/library/comparisons/NCT05894577-722f18ed",
"nct_id": "NCT05894577",
"kind": "outcome",
"participants": 1250,
"risk_difference": {
"value": -0.00003072070780510763,
"lower": -0.008773464999726624,
"upper": 0.00864103183992847
},
"group_1": "2 of 628",
"group_2": "2 of 622",
"difference": "-0.0 points",
"interval": "-0.9 to 0.9",
"trial_title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=244",
"request_id": "nJy-zPE80axGES0G"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant